Since some of them also lead to substantial weight loss, specific GLP-1 receptor agonists (GLP-1 RA), such as liraglutide 3 mg, are now also approved in some countries for the treatment of obesity in non-diabetic patients[136]. This evidence concerns the gene GLP1R and Obesity.